Cardiovascular and renal effects of nociceptin/orphanin FQ: A new mediator to target?

Current Opinion in Investigational Drugs

Volumn 8, Issue 9, 2007, Pages 742-749

  Doggrell, S A ^a  

^a Doggrell Biomedical Communications   (Australia)

Author keywords

Cardiovascular; Cerebrovascular; Nociceptin orphanin FQ; Opioid receptor like 1; Renal

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BINALTORPHIMINE; DYNORPHIN; NALOXONE; NITRIC OXIDE SYNTHASE INHIBITOR; NOCICEPTIN; NOCICEPTIN RECEPTOR AGONIST; PROPRANOLOL; RAUWOLSCINE; UFP 101; UFP 102; UFP 112; UNCLASSIFIED DRUG; ZP 120;

AORTA; ARTERIAL PRESSURE; BRADYCARDIA; BRAIN BLOOD VESSEL; BRAIN SLICE; CARDIOVASCULAR EFFECT; CORONARY ARTERY; DIURESIS; DRUG MECHANISM; EDEMA; HEART FAILURE; HYPONATREMIA; HYPOTENSION; IN VIVO STUDY; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY; LIVER CIRRHOSIS; MOUSE STRAIN; NONHUMAN; RAT STRAIN; REVIEW; SHEEP; SWINE;

ANIMALS; BLOOD PRESSURE; BRAIN; CARDIOVASCULAR SYSTEM; CEREBROVASCULAR CIRCULATION; DIURETICS; DRUG ADMINISTRATION ROUTES; HEART RATE; HUMANS; INJECTIONS, INTRAVENTRICULAR; KIDNEY; OPIOID PEPTIDES; PARASYMPATHETIC NERVOUS SYSTEM; RECEPTORS, OPIOID; RENAL CIRCULATION; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 34548300014     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Cox BM, Chavkin C, Christie MJ, Civelli O, Evans C, Hamon MD, Hoellt V, Kieffer B, Kitchen I, McKnight AT, Meunier AT et al: Opioid receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. Girdlestone D (Ed), IUPHAR Med Ltd, London, UK (2000):321-333.
2. Reinscheid RK, Nothacker H-P, Bourson A, Ardati A, Henningsen RA, Bunzow JR, Grandy DK, Langen H, Monsma FJ Jr, Civelli O: Orphanin FQ: A neuropeptide that activated an opioid like G protein-coupled receptor. Science (1995) 270(5237):792-794. •• Along with reference [3 ••], this was one of the first papers to describe the structure and function of N/OFQ.
3. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H et al: Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature (1995) 377(6549):532-535. •• Along with reference [2••], this was one of the first papers to describe the structure and function of N/OFQ.
4. Okuda-Ashitaka E, Ito S: Nocistatin: A novel neuropeptide encoded by the gene for the nociceptin/orphanin FQ precursor. Peptides (2000) 21(7):1101-1109.
5. Reinscheid RK: The orphanin FQ/nociceptin receptor as a novel drug target in psychiatric disorders. CNS Neurol Disord Drug Targets (2006) 5(2):219-224.
6. Wei Y, Ouyang D, Liu Y, Chang Z, Tang J, Ding J: Peripheral tissue distribution of orphanin FQ precursor mRNA in stroke-prone spontaneously hypertensive rats. Chin Med Sci J (1999) 14(2):67-70.
7. Gumusel B, Hao Q, Hyman A, Chang JK, Kapusta DR, Lippton H: Nociceptin: An endogenous agonist for central opioid like1 (ORL1) receptors possesses systemic vasorelaxant properties. Life Sci (1997) 60(8):PL141-PL145. • This was the first paper to describe the direct effects of N/OFQ on isolated blood vessels.
8. Granata F, Potenza RL, Fiori A, Strom R, Caronti B, Molinari P, Donsante S, Citro G, Iacovelli L, De Blasi A, Ngomba RT et al: Expression of OP4 (ORL1, NOP1) receptors in vascular endothelium. Eur J Pharmacol (2003) 482(1-3):17-23.
9. Hugghins SY, Champion HC, Cheng G, Kadowitz PJ, Jeter JR Jr: Vasorelaxant responses to endomorphins, nociceptin, albuterol, and adrenomedullin in isolated rat aorta. Life Sci (2000) 67(4):471-476.
10. Xu PH, Chang M, Cheng LX, Cheng Q, Yan X, Wang R: The relaxant effect of nociceptin on porcine coronary arterial ring segments. Can J Physiol Pharmacol (2004) 82(11):993-999.
11. 2, a new selective nociceptin receptor antagonist. Br J Pharmacol (2000) 129(6):1183-1193.
12. Champion HC, Pierce RL, Kadowitz PJ: Nociceptin, a novel endogenous ligand for the ORL1 receptor, dilates isolated resistance arteries from the rat. Regul Pept (1998) 78(1-3):69-74.
13. Bucher B: ORL1 receptor-mediated inhibition by nociceptin of noradrenaline release from perivascular sympathetic nerve endings of the rat tail artery. Naunyn Schmiedebergs Arch Pharmacol (1998) 358(6):682-685.
14. Giuliani S, Maggi CA: Prejunctional modulation by nociceptin of nerve-mediated inotropic responses in guinea-pig left atrium. Eur J Pharmacol (1997) 332(3):231-236.
15. Malinowska B, Godlewski G, Schlicker E: Function of nociceptin and opioid OP4 receptors in the regulation of the cardiovascular system. J Physiol Pharmacol (2002) 53(3):301-324.
16. Giuliana S, Tramontana M, Lecci A, Maggi CA: Effect of nociceptin on heart rate and blood pressure in anaesthetized rats. Eur J Pharmacol (1997) 333(2-3):177-179. • This was the first study to report the cardiovascular effects of N/OFQ in anesthetized animals.
17. Champion HC, Czapla MA, Kadowitz PJ: Nociceptin, an endogenous ligand for the ORL1 receptor, decreases cardiac output and total peripheral resistance in the rat. Peptides (1997) 18(5):729-732.
18. Guerrini R, Calo G, Rizzi A, Bigoni R, Bianchi C, Salvadori S, Regoli D: A new selective antagonist of the nociceptin receptor. Br J Pharmacol (1998) 123(2):163-165.
19. McDonald J, Barnes TA, Okawa H, Williams J, Calo' G, Rowbotham DJ, Lambert DG: Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: Studies using the ecdysone-inducible mammalian expression system. Br J Pharmacol (2003) 140(1):61-70.
20. Bigoni R, Giuliani S, Calo' G, Rizzi A, Guerrini R, Salvadori S, Regoli D, Maggi CA: Characterization of nociceptin receptors in the periphery: In vitro and in vivo studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 359(3):160-167.
21. Olianas MC, Concas D, Onali P: Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors. Br J Pharmacol (2006) 147(4):360-370.
22. Lin B, Waterman R, Lippton H: Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension. Life Sci (2000) 66(6):PL99-PL104.
23. Hashiba E, Hirota K, Kudo T, Calo' G, Guerrini R, Matsuki A: Effects of nociceptin/orphanin FQ receptor ligands on blood pressure, heart rate, and plasma catecholamine concentrations in guinea pigs. Naunyn Schmiedebergs Arch Pharmacol (2003) 367(4):342-347.
24. Czapla MA, Champion HC, Kadowitz PJ: Nociceptin, an endogenous ligand for the ORL1 receptor, has vasodilator activity in the hindquarters vascular bed of the rat. Peptides (1997) 18(6):793-795.
25. Champion HC, Bivalacqua TJ, Friedman DE, Zadina JE, Kastin AJ, Kadowitz PJ: Nitric oxide release mediates vasodilator responses to endomorphin 1 but not nociceptin/OFQ in the hindquarters vascular bed of the rat. Peptides (1998) 19(9):1595-1602.
26. Czapla MA, Champion HC, Kadowitz PJ: Decreases in systemic arterial hindquarters perfusion pressure in response to nociceptin are not inhibited by naloxone in the rat. Peptides (1997) 18(8):1197-1200.
27. Shimohigashi Y, Hatano R, Fujita T, Nakashima R, Nose T, Sujaku T, Saigo A, Shinjo K, Nagahisa A: Sensitivity of opioid receptor-like receptor ORL1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J Biol Chem (1996) 271(39):23642-23645.
28. 1]nociceptin analogs: Receptor binding and bioassay studies. Naunyn Schmiedebergs Arch Pharmacol (1999) 360(3):270-277.
29. 1]-nociceptin has naloxone-insensitive vasodilator activity in the hindquarters vascular bed of the rat. Life Sci (1997) 61(26):PL403-PL408.
30. 1]-nociceptin, a novel nociceptin analog, decreases systemic arterial pressure by a naloxone-insensitive mechanism in the rat. Biochem Biophys Res Commun (1997) 234(2):309-312.
31. Champion HC, Bivalacqua TJ, Rauchwarger A, McWilliams SM, McNamara DB, Kadowitz PJ: Analysis of vasodepressor responses to nociceptin and nociceptin analogs in the systemic vascular bed of the anesthetized rabbit in vivo. J Cardiovasc Pharmacol Ther (1998) 3(3):247-252.
32. Madeddu P, Salis MB, Milia AF, Emanueli C, Guerrini R, Regoli D, Calo G: Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension (1999) 33(3):914-919.
33. Rizzi A, Spagnolo B, Wainford RD, Fischetti C, Guerrini R, Marzola G, Baldisserotto A, Salvadori S, Regoli D, Kapustra DR, Calo G: In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. Peptides (2007) 28(6):1240-1251.
34. Nossaman BD, Champion HC, Kaye AD, Anwar M, Feng CJ, Kadowitz PJ: Nociceptin has vasodilator activity in the pulmonary vascular bed of the rat. J Cardiovasc Pharmacol Ther (1998) 3(3):253-258.
35. Abdelrahman AM, Pang CCY: Regional hemodynamic effects of nociceptin/orphanin FQ in the anesthetized rat. Eur J Pharmacol (2002) 450(3):263-266.
36. Arndt ML, Wu D, Soong Y, Szeto HH: Nociceptin/orphanin FQ increases blood pressure and heart rate via sympathetic activation in sheep. Peptides (1999) 20(4):465-470.
37. Salis MB, Emanueli C, Milia AF, Guerrini R, Madeddu P: Studies of the cardiovascular effects of nociceptin and related peptides. Peptides (2000) 21(7):985-993.
38. Kapusta DR: Neurohumoral effects of orphanin FQ/nociceptin: Relevance to cardiovascular and renal function. Peptides (2000) 21(7):1081-1099.
39. Helyes Z, Németh J, Pintér E, Szolcsányi J: Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol (1997) 121(4):613-615.
40. Habler H, Timmermann L, Stegmann J, Janig W: Effects of nociceptin and nocistatin on antidromic vasodilation in hairless skin of the rat hindlimb in vivo. Br J Pharmacol (1999) 127(7):1719-1727.
41. Champion HC, Wang R, Hellstrom WJ, Kadowitz PJ: Nociceptin, a novel endogenous ligand for the ORL1 receptor, has potent erectile activity in the cat. Am J Physiol (1997) 273(1 Pt 1):E214-E219.
42. 1]-nociceptin and nociceptin have similar naloxone-insensitive erectile activity in the cat. J Androl (1998) 19(6):747-753.
43. Neal CR, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Watson SJ Jr: Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. J Comp Neurol (1999) 406(4):503-547.
44. Lawrence AJ, Jarrott B: Neurochemical modulation of cardiovascular control in the nucleus tractus solitarius. Prog Neurobiol (1996) 48(1):21-53.
45. Anton B, Fein J, To T, Li X, Silberstein L, Evans CJ: Immuno-histochemical localization of ORL-1 in the central nervous system of the rat. J Comp Neurol (1996) 368(2):229-251.
46. Kapusta DR, Sezen SF, Chang J-K, Lippton H, Kenigs VA: Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci (1997) 60(1):PL15-PL21. • This paper describes the cardiovascular and renal effects of intracerebrovascular administration of N/OFQ.
47. 2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J Pharmacol Exp Ther (1999) 289(1):173-180.
48. Burmeister MA, Kapusta DR: Centrally administered nociception/orphanin FQ (N/OFQ) evokes bradycardia, hypotension, and diuresis in mice via activation of central N/OFQ peptide receptors. J Pharmacol Exp Ther (2007) 322(1):324-331.
49. Shirasaka T, Kunitake T, Kato K, Takasaki M, Kannan H: Nociceptin modulates renal sympathetic nerve activity through a central action in conscious rats. Am J Physiol (1999) 277(4 Pt 2):R1025-R1032.
50. 2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. J Pharmacol Exp Ther (2005) 312(3):1114-1123.
51. Kapusta DR, Dayan LA, Kenigs VA: Nociceptin/orphanin FQ modulates the cardiovascular, but not renal, responses to stress in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol (2002) 29(3):254-259.
52. Chu X, Xu N, Li P, Wang JQ: Profound inhibition of cardiomotor neurons in the rat rostral ventrolateral medulla by nociceptin (orphanin FQ). Neuroreport (1998) 9(6):1081-1084.
53. Chu X, Xu N, Li P, Wang JQ: The nociceptin receptor-mediated inhibition of the rat rostral ventrolateral medulla neurons in vitro. Eur J Pharmacol (1999) 364(1):49-53.
54. Chu X, Xu N, Li P, Mao L, Wang JQ: Inhibition of cardiovascular activity following microinjection of novel opioid-like neuropeptide nociceptin (orphanin FQ) into the rat rostral ventrolateral medulla. Brain Res (1999) 829(1-2):134-142.
55. Mao L, Wang JQ: Microinjection of nociceptin (orphanin FQ) into nucleus tractus solitarii elevates blood pressure and heart rate in both anesthetized and conscious rats. J Pharmacol Exp Ther (2000) 294(1):255-262.
56. Mao L, Wang JQ: Cardiovascular responses to microinjection of nociceptin and endomorphin-1 into the nucleus tractus solitarii in conscious rats. Neuroscience (2005) 132(4):1009-1015.
57. Mao L, Wang JQ: Pharmacological activation of nociceptin receptors in the nucleus tractus solitarius inhibits baroreflex in pentobarbital-anesthetized rats. Neuroscience (2000) 101(2):435-440.
58. Chitravanshi VC, Sapru HN: Mechanism of cardiovascular effects of nociceptin microinjected into the nucleus tractus solitarius of the rat. Am J Physiol Regul Integr Comp Physiol (2005) 288(6):R1553-R1562.
59. Spyer KM, Gilbey MP: Cardiorespiratory interactions in heart-rate control. Ann NY Acad Sci (1988) 533:350-357.
60. Venkatesan P, Wang J, Evans C, Irnaten M, Mendelowitz D: Nociceptin inhibits ̃-aminobutyric acidergic inputs to cardiac parasympathetic neurons in the nucleus ambiguous. J Pharmacol Exp Ther (2002) 300(1):78-82.
61. Venkatesan P, Baxi S, Evans C, Neff R, Wang X, Mendelowitz D: Glycinergic inputs to cardiac vagal neurons in the nucleus ambiguus are inhibited by nociceptin and μ-selective opioids. J Neurophysiol (2003) 90(3):1581-1588.
62. Chitravanshi VC, Sapru HN: Microinjections of nociceptin into the nucleus ambiguus elicits tachycardia in the rat. Brain Res (2005) 1051(1-2):199-204.
63. Krowicki ZK, Kapusta DR: Tonic nociceptinergic inputs to neurons in the hypothalamic paraventricular nucleus contribute to sympathetic vasomotor tone and water electrolyte homeostasis in conscious rats. J Pharmacol Exp Ther (2006) 317(1):446-453.
64. Ca channel activation. Brain Res (1999) 835(2):315-323.
65. Armstead WM: Relationship between nociceptin/orphanin FQ and cerebral hemodynamics after hypoxia-ischemia in piglets. Am J Physiol Heart Circ Physiol (2000) 278(2):H477-H483.
66. Armstead WM: NOC/oFQ contributes to hypoxic-ischemic impairment of N-methyl-D-aspartate-induced cerebral vasodilation. Brain Res (2000) 868(1):48-55.
67. Armstead WM: NOC/oFQ PKC-dependent superoxide generation contributes to hypoxic-ischemic impairment of NMDA cerebrovasodilation. Am J Physiol Heart Circ Physiol (2000) 279(6):H2678-H2684.
68. Kulkarni M, Armstead WM: Superoxide generation links nociceptin/orphanin FQ (NOC/oFQ) release to impaired N-methyl-D-aspartate cerebrovasodilation after brain injury. Stroke (2000) 31(8):1990-1996.
69. Hou M, Uddmann R, Tajti J, Edvinsson L: Nociceptin immunoreactivity and receptor mRNA in the human trigeminal ganglion. Brain Res (2003) 964(2):179-186.
70. Bartsch T, Akerman S, Goadsby PJ: The ORL-1 (NOP1) receptor ligand nociceptin/orphanin FQ (N/OFQ) inhibits neurogenic dural vasodilatation in the rat. Neuropharmacology (2002) 43(6):991-998. • This important paper describes the link between N/OFQ and migraine.
71. Ertsey C, Hantos M, Bozsik G, Tekes K: Circulating nociceptin levels during the cluster headache period. Cephalalgia (2004) 24(4):280-283.
72. Ertsey C, Hantos M, Bozsik G, Tekes K: Plasma nociceptin levels are reduced in migraine without aura. Cephalalgia (2005) 25(4):261-266.
73. Kapusta DR, Kenigs VA: Cardiovascular and renal responses produced by central orphanin FQ/nociceptin occur independent of renal nerves. Am J Physiol (1999) 277(4 Pt 2):R987-R995.
74. Kapusta DR, Burmeister MA, Calo' G, Guerrini R, Gottlieb HB, Kenigs VA: Functional selectivity of nociceptin/orphanin FQ peptide receptor agonists on cardiovascular and renal function. J Pharmacol Exp Ther (2005) 314(2):643-651. • This paper describes the distinguishable effects of N/OFQ on the cardiovascular and renal systems.
75. 2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity. J Pharmacol Exp Ther (2005) 314(2):652-660.
76. Rizzi A, Rizzi D, Marzola G, Regoli D, Larsen BD, Petersen JS, Calo' G: Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: In vitro and in vivo studies in mice. Br J Pharmacol (2002) 137(3):369-374.
77. Hardup N, Petersen JS, Praetorius J, Meier E, Graebe M, Brond L, Staahltoft D, Nielsen S, Christensen S, Kapusta DR, Jonassun TE: Opioid receptor-like 1 stimulation in the collecting duct induced aquaresis through vasopressin-independent aquaporin-2 down-regulation. Am J Physiol Renal Physiol (2004) 287(1):F160-F168. • This paper reports the aquaretic effect of N/OFQ in a rat model of heart failure.
78. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, Lundstrom K, Cesura AM, Poli SM, Roever S, Kolczewski S et al: A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytics profile in the rat. Proc Natl Acad Sci USA (2000) 97(9):4938-4943.
79. Kuzmin A, Sandin J, Terenius L, Ogren SO: Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors. Br J Pharmacol (2004) 141(1):132-140.
80. Chiou LC, Chuang KC, Wichmann J, Adam G: Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro-[4,5] decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices. J Pharmacol Exp Ther (2004) 311(2):645-651.
81. Dautzenberg FM, Wichmann J, Higelin J, Py-Lack G, Kratzeisen C, Malherbe P, Kilpartrick GJ, Jenck F: Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: Rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther (2001) 298(2):812-819.
82. Recker MD, Higgins GA: The opioid receptor like-1 receptor agonist Ro 64-6198 (1S,3aS-8-2,3,3 a,4,5,6-hexahydro-1H-phenalen-1-ylphenyl-1,3, 8-triaza-spiro[4.5]decan-4-one) produces a discriminative stimulus in rats distinct from that of a μ, κ, and δ opioid receptor agonist cue. J Pharmacol Exp Ther (2004) 311(2):652-658.
83. NCT00283361: ZP120 add-on to furosemide in treatment of acute or sub-acute decompensated heart failure. National Institutes of Health, Bethesda, MD, USA (2006). http://www.clinicaltrials.gov/ct/show/NCT00283361
84. Teshima K, Minoguchi M, Tounai S, Ashimori A, Eguchi J, Allen CN, Shibata S: Nonphotic entrainment of the circadian body temperature rhythm by the selective ORL1 receptor agonist W-212393. Br J Pharmacol (2005) 146(1):33-40.
85. Ozaki S, Kawamoto H, Itoh T, Miyaji M, Azuma T, Ichikawa D, Nambu H, Iguchi T, Iwasawa Y, Ohta H: In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist. Eur J Pharmacol (2000) 402(1-2):45-53.
86. De Risi C, Piero Pollini G, Trapella C, Peretto I, Ronzoni S, Giardina GA: A new synthetic approach to 1-[(3R,4R)-1- cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-benzimidazol- 2-one (J-113397), the first non-peptide ORL-1 receptor antagonist. Bioorg Med Chem (2001) 9(7):1871-1877.
87. Zeratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, Ronzoni S, Giardina GA, Schiedeler MA: Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin- 1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111). J Pharmacol Exp Ther (2004) 308(2):454-461.